The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pharmacokinetic (PK)-driven individualization of pazopanib therapy in patients with solid tumors: A phase 1 study (MC1112).
 
Keith Christopher Bible
No Relationships to Disclose
 
Pamela Jo Harris
No Relationships to Disclose
 
Jill K. Burton
No Relationships to Disclose
 
Jun Yin
No Relationships to Disclose
 
Rui Qin
No Relationships to Disclose
 
Daniel Satele
No Relationships to Disclose
 
Charles Erlichman
No Relationships to Disclose
 
Paul Haluska
Employment - Merck
Stock and Other Ownership Interests - Merck
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Ansh Laboratories (Inst); Boehringer Ingelheim
Research Funding - Clovis Oncology (Inst); Genentech (Inst); Nektar (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Mayo Ovarian Avatar Program- I have intellectual property related to this technology. Mayo Clinic and I received royalties on this technology
Travel, Accommodations, Expenses - Ansh Laboratories; Boehringer Ingelheim; Merck
 
Ramesh K. Ramanathan
Honoraria - Celgene; Cerulean Pharma; Lilly; Pharmacyclics; Taiho Pharmaceutical; Vaccinex
Consulting or Advisory Role - Celgene; Genentech; Lilly; Vaccinex
Research Funding - Abbvie; Bayer; Biomarin; Celgene; Genentech; Halozyme; Merck/Schering Plough; Merrimack; Sanofi; Tekmira; Vaccinex; Verastem
Travel, Accommodations, Expenses - Biomarin
Other Relationship - Celgene